Jennifer Griffin, Whitfield Growdon, M.D., Brandon Parry and Susanna Quinn join Prevent Cancer board of directors

Published on July 27, 2020

Jennifer Griffin, Whitfield Growdon, M.D., Brandon Parry and Susanna Quinn join Prevent Cancer board of directors

Contact: Lisa Berry Edwards

Alexandria, Va.—The Prevent Cancer Foundation® today announced the election of Jennifer Griffin, Whitfield (Whit) Growdon, M.D., Brandon Parry and Susanna Quinn to the Foundation’s board of directors.

“We are honored that Jennifer, Whit, Brandon and Susanna have agreed to serve on our board of directors,” said Carolyn Aldigé, Founder and CEO of the Prevent Cancer Foundation. “Each brings a unique set of talents and expertise to the board that will help the Foundation reach new heights in cancer prevention and early detection.”

“Whit, a cancer surgeon at Massachusetts General Hospital, has spent the entirety of his career helping people with cancer. As cancer survivors, Jennifer and Susanna know firsthand how critical this work is, as does Brandon, who lost his mother to cancer when he was a young child. Together, we will help countless people stop cancer before it starts,” Aldigé said.

Gary Lytle, Chairman of the Board, said, “It is my distinct honor to serve my next term alongside these four esteemed members of our community. As the Foundation celebrates 35 years of cancer prevention and early detection, we are looking ahead to achieve bold goals leading to a world without cancer.”

The Prevent Cancer Foundation is proud to welcome these four accomplished individuals to our board of directors.

Jennifer Griffin currently serves as a national security correspondent for FOX News Channel (FNC). She joined FNC in October 1999 as a Jerusalem-based correspondent. Prior to that, she reported from Moscow for three years. Before joining FNC, Ms. Griffin covered the Middle East region for several American media organizations, including National Public Radio and U.S. News and World Report. Previously, she reported for The Sowetan newspaper in Johannesburg, South Africa, where she covered Nelson Mandela’s prison release and numerous other historic moments in South Africa’s transition away from the apartheid regime.

She was diagnosed with stage 3 triple negative breast cancer in 2009. After 17 rounds of chemotherapy, a double mastectomy and radiation treatments, she was declared in remission in 2010.

Whitfield Growdon, M.D. is an assistant professor in Obstetrics, Gynecology and Reproductive Biology at Harvard Medical School and in the Division of Gynecologic Oncology at Massachusetts General Hospital (MGH). The majority of his efforts are dedicated to the care of women with gynecologic cancers, utilizing innovative surgical techniques, such as the robotic platform and single incision laparoscopy.

Dr. Growdon is a clinical investigator at Harvard’s Dana Farber Cancer Institute, responsible for enrolling patients on clinical trials. When not providing clinical care or teaching, Dr. Growdon focuses his efforts on laboratory research. The focus of the research is centered around characterizing actionable molecular drivers of ovarian and endometrial cancer and using in vivo models to test novel therapeutics to innovate treatment for tumors harboring those specific alterations. The vision is one of precision medicine where each tumor can be explored for an Achilles heel that can then be exploited to meaningfully alter the trajectory of a woman’s cancer.

Brandon Parry is a partner in McKinsey’s Washington, D.C., office and a leader in the Pharmaceuticals & Medical Products Practice. For the past decade, Mr. Parry has focused on biopharma research and development (R&D), working with both public-sector clients and private-sector sponsors on issues across the R&D value chain.

Mr. Parry serves clients on a wide range of topics related to R&D optimization, with a particular focus on drug safety, regulatory affairs, and clinical development. Mr. Parry also helps lead McKinsey’s global work with medical-products regulators. Prior to joining McKinsey, Brandon worked in life-sciences venture capital, where he invested in and built businesses focused on oncology, immunology and orphan diseases.

Susanna Quinn is an entrepreneur and writer. She was CEO and founder of Veluxe, an app-powered on-demand service that connected busy influencers with a roster of top-rated beauty, fitness and wellness experts in Washington, D.C., Baltimore, Philadelphia and Chicago. In August 2018, she sold Veluxe to Glamsquad, where she became a senior advisor. Prior to founding Veluxe, Mrs. Quinn worked as a research assistant, legislative aide and deputy chief of staff in the United States Congress and as a freelance writer. Her writing has appeared in the Washington PostHuffington Post, Washington Times and Capitol File magazine.

In March 2019, Mrs. Quinn was diagnosed with stage three ovarian cancer. She underwent an aggressive debulking surgery followed by six grueling rounds of chemotherapy. She was declared cancer-free in the fall of 2019. 

Despite their busy and successful careers, each of these individuals is devoted to their communities, their spouses and their children.  We are so fortunate they are now devoted to the Prevent Cancer Foundation.

About The Prevent Cancer Foundation

The Prevent Cancer Foundation is one of the nation’s leading voluntary health organizations and the only U.S. nonprofit organization focused solely on cancer prevention and early detection. Founded in 1985, it has catapulted cancer prevention to prominence and fulfills its mission through research, education, outreach and advocacy.

Sign up to get the latest about cancer prevention and early detection directly in your inbox.